Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis

Chest

Volumn 149, Issue 2, 2016, Pages 390-400

  Salsgiver, Elizabeth L ^a,e   Fink, Aliza K ^b   Knapp, Emily A ^b   LiPuma, John J ^c   Olivier, Kenneth N ^d   Marshall, Bruce C ^b   Saiman, Lisa ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b CYSTIC FIBROSIS FOUNDATION   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Cystic fibrosis; Pseudomonas aeruginosa; Registry; Staphylococcus aureus

Indexed keywords

ACHROMOBACTER XYLOSOXIDANS; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIUM CULTURE; BURKHOLDERIA CEPACIA COMPLEX; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; EPIDEMIOLOGICAL DATA; HAEMOPHILUS INFLUENZAE; HUMAN; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NEWBORN; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT; BACTERIAL INFECTIONS; BACTERIUM; CLINICAL TRIAL; COMPLICATION; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MORTALITY; MULTICENTER STUDY; REGISTER; RESPIRATORY SYSTEM; SEX RATIO; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BACTERIA; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; PREVALENCE; REGISTRIES; RESPIRATORY SYSTEM; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 84958093779     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0676     Document Type: Article

References (42)

1. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183(11): 1463-1471.
2. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161(4):233-241.
3. Ciofu O, Hansen CR, Høiby N. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med. 2013;19(3): 251-258.
4. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest. 2009;136(6):1554-1560.
5. LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23(2):299-323.
6. Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16(7):821-830.
7. Cystic Fibrosis Foundation. National Patient Registry 2012 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2013.
8. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol. 2010;45(4):363-370.
9. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros. 2009;8(6):386-391.
10. Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros. 2011;10(6): 466-469.
11. Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis. 2009;28(2):191-195.
12. Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J. 2004;23(1):98-102.
13. Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis. 2008;14(3):378-384.
14. Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J. 2005;25(2): 324-328.
15. Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol. 2005;43(7):3467-3470.
16. Samra Z, Kaufman L, Pitlik S, Shalit I, Bishara J. Emergence of Mycobacterium simiae in respiratory specimens. Scand J Infect Dis. 2005;37(11-12):838-841.
17. Leung JM, Olivier KN. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med. 2013;19(6):662-669.
18. Thomson RM; NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16(10): 1576-1583.
19. Schechter MS, Fink AK, Homa K, Goss CH. The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement. BMJ Qual Saf. 2014;23(suppl 1):i9-i14.
20. Floto RA, Olivier KN, Saiman L, et al. Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of nontuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(suppl 1):1-22.
21. Cystic Fibrosis Foundation. National Patient Registry 2013 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2014.
22. Saiman L, Siegel J, Foundation CF; Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003;24(5)(Suppl):S6-S52.
23. Saiman L, Siegel JD, LiPuma JJ, et al; Cystic Fibrous Foundation. Society for Healthcare Epidemiology of America. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(suppl 1):S1-S67.
24. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847-856.
25. Ratjen F, Munck A, Kho P, Angyalosi G, Group ES; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286-291.
26. Dantes R, Mu Y, Belflower R, et al; Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970-1978.
27. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts. Pediatr Infect Dis J. 2009;28(10):895-899.
28. Glikman D, Siegel JD, David MZ, et al. Complex molecular epidemiology of methicillin-resistant staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic communityassociated methicillin-resistant S aureus. Chest. 2008;133(6):1381-1387.
29. Champion EA, Miller MB, Popowitch EB, Hobbs MM, Saiman L, Muhlebach MS; STAR-CF Study Team. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis. Pediatr Pulmonol. 2014;49(3):230-237.
30. Muhlebach MS, Miller M, LaVange LM, Mayhew G, Goodrich JS, Miller MB. Treatment intensity and characteristics of MRSA infection in CF. J Cyst Fibros. 2011;10(3):201-206.
31. Savant AP, O'Malley C, Bichl S, McColley SA. Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures. BMJ Qual Saf. 2014;23(suppl 1): i73-i80.
32. Goss CH, Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros. 2011;10(5):298-306.
33. Jennings MT, Boyle MP, Weaver D, Callahan KA, Dasenbrook EC. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis-the PMEP trial: study protocol for a randomized controlled trial. Trials. 2014;15:223.
34. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2-41.
35. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol. 1998;36(7):1953-1958.
36. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381(9877):1551-1560.
37. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185(2):231-232.
38. Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med. 2014;190(5):581-586.
39. Peeters C, Zlosnik JE, Spilker T, Hird TJ, LiPuma JJ, Vandamme P. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol. 2013;36(7):483-489.
40. Spilker T, Vandamme P, LiPuma JJ. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros. 2013;12(3):298-301.
41. Heltshe SL, Mayer-Hamblett N, Burns JL, et al; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60(5):703-712.
42. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al; Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640-1650.